Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the rectum below 10 cm from the anal verge
2. Locally advanced rectal cancer (T3N0 or T1-3N+)
3. Age: 19-80 years old.
4. Without evidence of distant metastasis including paraortic lymph node, common \& external iliac lymph node metastasis
5. MRI scan confirmed more than 2 mm circumferential margin
6. ECOG(Eastern Cooperative Oncology Group) performance status 0-2
7. preoperative ASA class I-III
8. No prior systemic treatment for rectal cancer (i.e. chemotherapy or immunotherapy)
9. No history of regional radiation treatment in the pelvic cavity
10. Adequate hematologic function: ANC(absolute neutrophil count) ≥ 1.5×109/L，Platelet ≥ 100×109/L, Adequate renal function: Cr ≤ 1.5×ULN or Glomerular filtration rate (Ccr calculated by Cockcroft formula) ≥ 50 ml/min, Adequate hepatic function: ALT(Alanine aminotransferase)/AST(aspartate aminotransferase) ≤ 2.5×ULN, Total bilirubin ≤ 1.5×ULN
11. Patients must be willing and able to comply with the protocol duration of the study
12. Signed informed consent

Exclusion Criteria:

1. Malignancy of the rectum other than adenocarcinoma or adenocarcinoma developed from inflammatory bowel disease
2. Suspicious distant metastasis
3. Patients with peripheral neuropathy ≥ NCI CTC(common terminology criteria) grade 1
4. Uncontrolled and significant cardiovascular disease (i.e. NYHA(New York Heart Association) class III or IV heart failure, myocardial infarction within the past 6 months, uncontrolled angina pectoris)
5. Uncontrolled active infection or serious concomitant systemic disorders incompatible with the study
6. Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin
7. Patients requiring immunosuppressive treatment who received organ transplantation
8. Uncontrolled epilepsy and psychiatric disease
9. Pregnant or lactating patient
10. Females with a positive or no pregnancy test unless childbearing potential can be otherwise excluded (amenorrheic for at least 2 years,hysterectomy or oophorectomy)
11. Patients receiving a concomitant treatment with drugs interacting with 5-Fluorouracil or oxaliplatin such as flucytosine, phenytoin, or warfarin
12. Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-Fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency.
13. Known hypersensitivity to platinum-based drugs, leucovorin or capecitabine
14. Patients taking sorivudine or brivudine
15. Patients taking tegafur, gimeracil, oteracil potassium complex or stopped the medication within 7days before.
16. Patients who have hereditary disease like as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.
17. Participant in any clinical trial within 4 weeks before initiation of the study
18. Treatment with bevacizumab, cetuximab, oxaliplatin or irinotecan before screening